|
|||||
|
|
Potential kidney protection with liraglutide and semaglutide: Exploratory mediation analysis |
|
| Authors: | Johannes F. E. Mann MD John B. Buse MD Thomas Idorn MD Lawrence A. Leiter MD Richard E. Pratley MD Søren Rasmussen PhD Tina Vilsbøll MD Benjamin Wolthers MD Vlado Perkovic MD |
| Affiliation: | 1. Department of Nephrology, Friedrich Alexander University of Erlangen, Erlangen, Germany;2. University of North Carolina School of Medicine, Chapel Hill, North Carolina, USA;3. Novo Nordisk A/S, Søborg, Denmark;4. Li Ka Shing Knowledge Institute, St. Michael's Hospital, University of Toronto, Toronto, Ontario, Canada;5. AdventHealth Translational Research Institute, Orlando, Florida, USA;6. Steno Diabetes Centre Copenhagen, Gentofte, Denmark Gentofte Hospital, Hellerup, Denmark University of Copenhagen, Copenhagen, Denmark;7. The George Institute, UNSW, Sydney, New South Wales, Australia |
| Abstract: | |
| Keywords: | chronic kidney disease glucagon-like peptide-1 receptor agonist kidney mediation liraglutide semaglutide type 2 diabetes |